ZGEN: Clark seemed to be saying the AE were worse than expected for inf-lambda. There is also some risk of an all oral compound replacing interferon and ribavirin. The stock doesn't seem to be doing anything at all. I don't have any stock specific stock I want to buy though. I am extremely overweight INSM but so far it is working out great. Since the end of last november this has been the best run (up 10x in one of my main accounts) I have ever had.
Market Data 
Markets 
AI
